The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging.
Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials.
Written by:
Acar O, Esen T, Lack NA. Are you the author?
VKF American Hospital, Guzelbahce sokak, Nisantasi, Istanbul 34365, Turkey.
Reference: ScientificWorldJournal. 2013 May 27;2013:379641.
doi: 10.1155/2013/379641
PubMed Abstract
PMID: 23781155
